JG

Jacqueline Grant

Biotech Investor at Abingworth

Boston, Massachusetts

Investor
VC

Invests in

Stages:

Series A

  • Min Investment:

    $15,000,000.00

  • Max Investment:

    $30,000,000.00

  • Target Investment:

    $22,500,000.00

Skills

Strategy
Research
Neuroscience
Data Analysis
Management
Financial Modeling
Science
Laboratory
Strategic Planning
Business Development

Education

Investments

Atsena Therapeutics

Series A

Total Funding: $55M

Work Experience

Harvard Business School

2023

  • Executive Fellow

    2023

    Guest lecturer and creator of educational content for VC/entrepreneurship/life sciences.

Nido Biosciences

2020

  • Member Board of Directors

    2020

Atsena Therapeutics

2021

  • Member Board of Directors

    2021

Glycomine Inc.

2022

  • Member Board of Directors

    2022

Anjarium Biosciences

2021

  • Board Observer

    2021

Abingworth

2018

  • Principal

    2018

SV Life Sciences

2017 - 2018

  • Senior Associate

    2017 - 2018

Genentech

2014 - 2016

  • Senior Manager, Business Development

    2016 - 2016

  • Manager Business Development

    2015 - 2016

  • Associate, Business Development

    2014 - 2015

Genentech

2013 - 2013

  • MBA Marketing & Commercialization Intern

    2013 - 2013

Stanford University

2008 - 2012

  • PhD Neuroscience

    2008 - 2012

    Faculty Advisor: Larry Steinman Utilize transgenic mouse models, in vivo and in vitro molecular and cellular techniques to study the disease pathogenesis and discover therapeutic agents for Multiple Sclerosis and Alzheimer’s disease. Grant et al., Science Translational Medicine, 08/01/12 Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis